Supernus Pharmaceuticals, Inc. ( SUPN) - Key Metrics
SUPN Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $3.77 | -$1.01 | -$0.08 | -$0.09 |
| 2026Q1 | $3.60 | -$0.04 | $1.15 | $1.15 |
| 2025Q4 | $3.69 | -$0.07 | $0.35 | $0.34 |
| 2025Q3 | $3.41 | -$0.80 | -$1.09 | -$1.10 |
| 2025Q2 | $2.95 | $0.40 | $1.04 | $1.04 |
SUPN Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -11.51 |
| 2026Q1 | 0% | -324.69 |
| 2025Q4 | 0% | -173.53 |
| 2025Q3 | 0% | -14.93 |
| 2025Q2 | 0% | 19.70 |
SUPN
Price: $39.57
52 week price:
Earnings Per Share: -1.90 USD
Exchange: NGM
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: United States
Volume: 524852
Ebitda: 27.4 millionMarket Capitalization: 2.5 billion